Background and Purpose Cancer patients are at increased risk of cardiovascular and cerebrovascular events. It is unclear whether cancer confers any additional risk for recurrent stroke or cardiovascular mortality after stroke. Methods This was a single center, observational study of 1,105 consecutive Chinese ischemic stroke patients recruited from a large stroke rehabilitation unit based in Hong Kong. We sought to determine whether patients with cancer are at higher risk of recurrent stroke and cardiovascular mortality. Results Amongst 1,105 patients, 58 patients (5.2%) had cancer, of whom 74% were in remission. After a mean follow-up of 76±18 months, 241 patients developed a recurrent stroke: 22 in patients with cancer (38%, annual incidence 13.94%/year), substantially more than those without cancer (21%, 4.65%/year) (p<0.01). In a Cox regression model, cancer, age and atrial fibrillation were the 3 independent predictors of recurrent stroke with a hazard ratio (HR) of 2.42 (95% confidence interval (CI): 1.54–3.80), 1.01 (1.00–1.03) and 1.35 (1.01–1.82) respectively. Likewise, patients with cancer had a higher cardiovascular mortality compared with those without cancer (4.30%/year vs. 2.35%/year, p = 0.08). In Cox regression analysis, cancer (HR: 2.08, 95% CI: 1.08–4.02), age (HR: 1.04, 95% CI 1.02–1.06), heart failure (HR: 3.06, 95% CI 1.72–5.47) and significant carotid atherosclerosis (HR: 1.55, 95% CI 1.02–2.36) were independent predictors for cardiovascular mortality. Conclusions Stroke patients with a past history of cancer are at increased risk of recurrent stroke and cardiovascular mortality.
References
[1]
Graus F, Rogers LR, Posner JB (1985) Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64: 16–35. doi: 10.1097/00005792-198501000-00002
[2]
Grisold W, Oberndorfer S, Struhal W (2009) Stroke and cancer: a review. Acta Neurol Scand 119: 1–16. doi: 10.1111/j.1600-0404.2008.01059.x
[3]
Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, et al. (2000) Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke 31: 1062–1068. doi: 10.1161/01.str.31.5.1062
[4]
Sumer M, Ozdemir I, Erturk O (2003) Progression in acute ischemic stroke: frequency, risk factors and prognosis. J Clin Neurosci 10: 177–180. doi: 10.1016/s0967-5868(02)00325-9
[5]
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, et al.. (2013) An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation.
[6]
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; a journal of cerebral circulation 24: 35–41. doi: 10.1161/01.str.24.1.35
[7]
Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, et al. (2012) Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke; a journal of cerebral circulation 43: 3029–3034. doi: 10.1161/strokeaha.112.658625
[8]
Kim SG, Hong JM, Kim HY, Lee J, Chung PW, et al. (2010) Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke; a journal of cerebral circulation 41: 798–801. doi: 10.1161/strokeaha.109.571356
[9]
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, et al. (2012) Third universal definition of myocardial infarction. Journal of the American College of Cardiology 60: 1581–1598. doi: 10.1038/nrcardio.2012.122
[10]
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977–2016. doi: 10.1161/circulationaha.109.192064
[11]
Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, et al. (2011) 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 58: 2020–2045. doi: 10.1161/cir.0b013e31822e80c3
[12]
Lai SM, Alter M, Friday G, Sobel E (1994) A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke; a journal of cerebral circulation 25: 958–962. doi: 10.1161/01.str.25.5.958
[13]
Chaturvedi S, Ansell J, Recht L (1994) Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke; a journal of cerebral circulation 25: 1215–1218. doi: 10.1161/01.str.25.6.1215
[14]
Kim JM, Jung KH, Park KH, Lee ST, Chu K, et al. (2013) Clinical manifestation of cancer related stroke: retrospective case-control study. Journal of neuro-oncology 111: 295–301. doi: 10.1007/s11060-012-1011-4
[15]
Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM (2004) Stroke in patients with cancer: incidence and etiology. Neurology 62: 2025–2030. doi: 10.1212/01.wnl.0000129912.56486.2b
[16]
Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. The lancet oncology 6: 401–410. doi: 10.1016/s1470-2045(05)70207-2
[17]
Verso M, Agnelli G, Ageno W, Imberti D, Moia M, et al. (2012) Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thrombosis research 130: 369–373. doi: 10.1016/j.thromres.2012.04.003
[18]
Alvarez-Perez FJ, Verde I, Uson-Martin M, Figuerola-Roig A, Ballabriga-Planas J, et al. (2012) Frequency and mechanism of ischemic stroke associated with malignancy: a retrospective series. European neurology 68: 209–213. doi: 10.1159/000341343
[19]
Plummer C, Henderson RD, O’Sullivan JD, Read SJ (2011) Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke; a journal of cerebral circulation 42: 2410–2418. doi: 10.1161/strokeaha.111.615203
[20]
Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, et al. (2005) Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103: 994–999. doi: 10.1002/cncr.20893
[21]
Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, et al. (2003) Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. Journal of pediatric hematology/oncology 25: 484–487. doi: 10.1097/00043426-200306000-00011
[22]
Wiviott SD, Cannon CP (2006) The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current opinion in lipidology 17: 626–630. doi: 10.1097/mol.0b013e328010872d
[23]
Elkind MS, Flint AC, Sciacca RR, Sacco RL (2005) Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 65: 253–258. doi: 10.1212/01.wnl.0000171746.63844.6a
[24]
Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, et al. (2012) Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke; a journal of cerebral circulation 43: 147–154. doi: 10.1161/strokeaha.111.627729
[25]
Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. The New England journal of medicine 367: 1792–1802. doi: 10.1056/nejmoa1201735
